Citigroup Upgrades Alexion Pharma to Buy from Hold
Citigroup upgraded Alexion Pharmaceuticals, Inc.(Nasdaq GM: ALXN). Citigroup has raised its target on shares to $55 from $45 on expectations sales of Soliris to drive better than expected earnings and guidance.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.